European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.","authors":"Riccardo Laudicella,Antongiulio Faggiano,Valeria Pirro,Rexhep Durmo,Pierpaolo Salsi,Roberta Modica,Luca Urso,Chiara Maria Grana,Daniele Sances,Maria Rinzivillo,Manuela Albertelli,Francesca Spada,Stefano Partelli,Francesco Ferraù,Nicola Fazio,Salvatore Tafuto,Marco Maccauro,Mirco Bartolomei,Francesco Panzuto,Maria Luisa De Rimini,Secondo Lastoria,Angelina Filice","doi":"10.1007/s00259-025-07596-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07596-2","url":null,"abstract":"PURPOSECarcinoid syndrome (CS) is the most frequent neuroendocrine tumor (NET)-related syndrome with variable presentations related to hormonal discharge and long-term complications, such as carcinoid heart disease (CHD). Carcinoid crisis (CC) is an acute and serious CS complication, due to a massive release of vasoactive hormones and biologically active substances, which may occur during stressogenic procedures such as peptide receptor radionuclide therapy (PRRT). CC is an emergency and life-threatening condition that needs to be prevented, promptly recognized, and managed. The purpose of this joint Italian multidisciplinary position paper is to support the involved personnel in delivering [177Lu]Lu-based PRRT to syndromic NET patients, focusing on CC management.METHODSThe literature evidence regarding CS, CHD, and CC during/after PRRT and the knowledge of 22 Italian NET experts in Anesthesiology, Endocrinology, Gastroenterology, Nuclear Medicine, Oncology, and Surgery involved in PRRT were the basis for the present document.RESULTSThe expert panel expressed several recommendations regarding: 1) CC high-risk patients identification; 2) CC prevention, including considerations of the behavioral and nutritional status, and somatostatin analogue therapy; 3) how to implement PRRT premedication in CC high-risk patients; 4) how to manage CC during PRRT, including post-PRRT monitoring, and radiation protection considerations.CONCLUSIONThis practical guide summarizes the views and experience in CS, CHD, and CC in relation to PRRT of a joint NET-dedicated Italian multidisciplinary team. These recommendations should be taken into the context of Nuclear Medicine good practice and do not substitute any national and International legal or regulatory provisions.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145235646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical utility of total-body [68 Ga]Ga-PSMA-11 PET/CT in prostate cancer: identifying extra-regional bone metastases and informing treatment strategies.","authors":"Qiaochu Chen,Wei Wang,Yining Wang,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Liu Liu,Ruohua Chen,Jianjun Liu","doi":"10.1007/s00259-025-07581-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07581-9","url":null,"abstract":"BACKGROUND AND PURPOSEBone metastasis significantly impacts morbidity and mortality in prostate cancer patients, necessitating accurate detection and monitoring. Although [68 Ga]Ga-PSMA-11 PET/CT imaging provides superior sensitivity compared with conventional imaging, the conventional field of view (CFOV; skull to proximal femur) obtained with short axial field of view (SAFOV) PET/CT scanners may underestimate the extent of disease. This study aimed to evaluate the prevalence and characteristics of bone metastases outside the CFOV scan range (distal to the proximal one-third of the femur) using total-body [68 Ga]Ga-PSMA-11 PET/CT imaging and its impact on tumor burden, staging and subsequent treatment in prostate cancer patients.METHODSThis retrospective study included 1211 prostate cancer patients who underwent total-body [68 Ga]Ga-PSMA-11 PET/CT imaging. Imaging results were independently evaluated by three nuclear medicine physicians. Positive findings were validated through histopathology, treatment response, prostate-specific antigen (PSA) changes, or follow-up imaging. We further characterized the clinical and imaging characteristics of lesions located beyond the CFOV scan range. We also assessed the impact of total-body imaging on tumor burden biomarkers (PSMA-TV and TL-PSMA) and disease staging, and constructed a nomogram to predict the risk of extra-CFOV lesions.RESULTSApart from bone metastases, total-body [68 Ga]Ga-PSMA-11 PET/CT imaging did not identify any other types of lesions outside the CFOV scan range. Among the 1211 patients, 5.12% (62 patients) had bone metastases outside the CFOV scan range. Multivariable regression analysis revealed that patients in the castration-resistant prostate cancer (CRPC) stage, with higher Gleason scores (≥ 8), and higher PSA levels (≥ 12.57 ng/mL) were independent predictors of bone metastases outside the CFOV scan range. We developed a nomogram to predict bone metastases outside the CFOV scan range, in which the patient's disease stage demonstrated greater predictive value than the Gleason score and PSA level. In the subset of 62 patients with lesions outside the CFOV scan range, tumor burden metrics were significantly increased (P < 0.001). Treatment plans were altered in 20 patients (32.3% of the subgroup; 1.65% of the total cohort).CONCLUSIONSSAFOV PET/CT scanners with CFOV scan range may underestimate the true extent of bone metastasis. Total-body scan range using total-body PET/CT scanners revealed occult bone metastases in 5.12% of patients, particularly in those with higher PSA, Gleason scores, and CRPC stage. This extended view significantly impacts tumor burden quantification, leads to disease upstaging, and influences treatment planning. The developed nomogram can guide clinicians at centers with SAFOV PET/CT scanners in identifying patients who would most benefit from extended field-of-view imaging.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"63 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145229105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Texture analysis of [18F]FDG PET/CT may stratify risk in stage II colorectal cancer - discovery findings.","authors":"Louise Rice,Balaji Ganeshan,Simon Wan,Shih-Hsin Chen,David M L Lilburn,Manuel Rodriguez-Justo,Stuart Taylor,Robert I Shortman,Raymond Endozo,Saif Khan,Luke R Hoy,Daren Francis,Tan Arulampalam,Nicholas Reay-Jones,Kenneth A Miles,Ashley M Groves","doi":"10.1007/s00259-025-07568-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07568-6","url":null,"abstract":"RATIONALEIt is challenging to identify which patients with Stage II colorectal cancer (T3N0M0 and T4N0M0) are at high risk of recurrence and might benefit from additional therapies. This preliminary study examines whether multiparametric [18F]FDG PET/CT is superior to T-stage in predicting overall survival in this patient group.MATERIALS AND METHODSThis multicentre, prospective observational study included 66 patients (41 male, 25 female, mean age 69.1 ± 10.3yrs) with biopsy-proven Stage II colorectal cancer who underwent [18F]FDG PET/CT prior to resection. Kaplan-Meier analysis was performed on PET and image texture parameters and clinico-histopathological markers to identify associations with survival. P-values were adjusted using the Benjamini-Hochberg procedure, and the most statistically significant radiomic parameters underwent 3-fold cross-validation. Multivariate Cox regression analysis was used to determine independence of prognostic markers.RESULTS49 patients survived the follow up period, with a mean overall survival of 88.4 (± 42.3 months). Univariate analysis showed no significant survival association with clinical variables such as patient sex (p = 0.295), age (p = 0.085), tumour side (p = 0.662), location (p = 0.848) or volume (p = 0.782), or high-risk histopathological metrics including low number lymph node sampling (p = 0.363), perineural, lymphovascular or extramural tumour invasion (p = 0.196), poor tumour differentiation (p = 0.372), and tumour perforation (p = 0.475). No significant survival difference was observed between T3 and T4-stages (p = 0.748). An increased mortality risk was observed for patients with a pixel mean intensity < 20.390 on CT texture (coarse texture scale), HR: 3.40 (1.36-8.49); p = 0.005, and where SUVmax ≥ 25.560 g/mL on [18F]FDG PET/CT, HR: 3.45 (1.31-9.12); p = 0.008. These parameters remained significant after 3-fold cross validation and were independent predictors of survival after Multivariate Cox regression analysis. A higher mortality risk was indicated when the parameters were combined (5 of 66 patients), hazard ratio: 5.44 (1.75-16.91); p = 0.001.CONCLUSIONMultiparametric [18F]FDG PET/CT can potentially provide prognostic markers for patients with stage II colorectal cancer with superior risk stratification compared to T-stage.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"18 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145229227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain metabolic imaging with 18 F-PET-CT and machine-learning clustering analysis reveal divergent metabolic phenotypes in patients with amyotrophic lateral sclerosis.","authors":"Jinfan Zhang,Fuchang Han,Xueying Wang,Feifei Wu,Xinyu Song,Qing Liu,Junling Wang,Alessandro Grecucci,Yuanchao Zhang,Xiaoping Yi,Bihong T Chen","doi":"10.1007/s00259-025-07585-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07585-5","url":null,"abstract":"BACKGROUNDAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by significant clinicopathologic heterogeneity. This study aimed to identify distinct ALS phenotypes by integrating brain 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (18 F-FDG PET-CT) metabolic imaging with consensus clustering data.METHODSThis study prospectively enrolled 127 patients with ALS and 128 healthy controls. All participants underwent a brain 18 F-FDG-PET-CT metabolic imaging, psychological questionnaires, and functional screening. K-means consensus clustering was applied to define neuroimaging-based phenotypes. Survival analyses were also performed. Whole exome sequencing (WES) was utilized to detect ALS-related genetic mutations, followed by GO/KEGG pathway enrichment and imaging-transcriptome analysis based on the brain metabolic activity on the 18 F-FDG-PET-CT imaging.RESULTSConsensus clustering identified two metabolic phenotypes, i.e., the metabolic attenuation phenotype and the metabolic non-attenuation phenotype according to their glucose metabolic activity pattern. The metabolic attenuation phenotype was associated with worse survival (p = 0.022), poorer physical function (p = 0.005), more severe depression (p = 0.026) and greater anxiety level (p = 0.05). WES testing and neuroimaging-transcriptome analysis identified specific gene mutations and molecular pathways with each phenotype.CONCLUSIONSWe identified two distinct ALS phenotypes with varying clinicopathologic features, indicating that the unsupervised machine learning applied to PET imaging may effectively classify metabolic subtypes of ALS. These findings contributed novel insights into the heterogeneous pathophysiology of ALS, which should inform personalized therapeutic strategies for patients with ALS.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"214 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-tracer PET/CT with [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 improves early prediction of biochemical failure in prostate cancer: a prospective phase II trial.","authors":"Jinhui Yang,Yujia Li,Yongxiang Tang,Bei Chen,Ling Xiao,Axel Rominger,Kuangyu Shi,Ming Zhou,Jian Li,Yi Cai,Tao Jiang,Shuo Hu","doi":"10.1007/s00259-025-07574-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07574-8","url":null,"abstract":"PURPOSEProstate-specific membrane antigen (PSMA) and Gastrin-releasing peptide receptor (GRPR) PET demonstrate hopeful results in initial staging of prostate cancer (PCa), offering potential to support precision treatment decisions. We investigated whether the dual-tracer PET/CT with [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 could enhance prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) in PCa.METHODS102 patients from prospective cohort NCT05073653 underwent preoperative [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 PET/CT. Tumor uptake was quantified by maximum standardized uptake value (SUVmax), with optimal cutoffs determined using maximally selected rank statistics. Biochemical recurrence-free survival (BRFS) was estimated by Kaplan-Meier analysis, and the correlations between BRFS and predictors were examined using Cox regression. Predictive values were assessed using time-dependent receiver-operating characteristic (ROC) curves. We additionally used transcriptomic data (GSE70770, n = 198) for external validation.RESULTS52 patients (51.0%) experienced BCR within the follow-up (median, 22.3 months). High PSMA-SUVmax (> 6.6) was associated with shorter BRFS (hazard ratio [HR] 3.17, p = 0.004), as was low GRPR-SUVmax (≤ 13.0) (HR 0.51, p = 0.026). Both were identified as independent predictors for BRFS. PSMA-SUVmax correlated with most of conventional clinicopathological factors (p < 0.005), whereas GRPR-SUVmax did not (p > 0.200). The combined PSMA + GRPR-SUVmax model achieved a superior time-dependent AUC of 0.73, compared with PSMA (AUC 0.63) or GRPR alone (AUC 0.62). External transcriptomic analysis corroborated that PSMAhigh/GRPRlow phenotype was associated with poorer BRFS (p = 0.029).CONCLUSIONThis study provides first clinical evidence that [68Ga]Ga-RM26 PET/CT adds independent prognostic value to PSMA PET/CT for early prediction of BCR after RP. Dual-tracer PET/CT may enable more accurate risk stratification and guide personalized management in PCa patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"76 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report.","authors":"Oliver Lindner,J Bucerius,B Burchert,T Derlin,R R Buechel","doi":"10.1007/s00259-025-07601-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07601-8","url":null,"abstract":"PURPOSEBone scintigraphy using technetium-99 m-labelled phosphonates is increasingly applied for imaging of cardiac transthyretin (ATTR) amyloidosis. However, there is limited data on how frequently this technique is used.MATERIALS AND METHODSTo address this issue, we added questions about the number of patients referred for nuclear medicine scanning for suspected cardiac amyloidosis and the proportion of positive results (Perugini score of 2 or 3) to the 2024 survey on myocardial perfusion imaging conducted jointly in Germany, Austria and Switzerland.RESULTSThe number of participating institutions in Austria, Germany and Switzerland was 12, 170 and 16, respectively. The number of patients scanned for cardiac amyloidosis was 1487, 4029 and 824 with a positivity-rate of 41%, 37% and 49%.CONCLUSIONThe survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"114 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG-PET reveals early postoperative cortical dysfunction after subthalamic nucleus deep brain stimulation in Parkinson's disease.","authors":"Christian Volz,Volker A Coenen,Lars Frings,Michel Rijntjes,Horst Urbach,Philipp T Meyer,Bastian E A Sajonz,Joachim Brumberg","doi":"10.1007/s00259-025-07552-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07552-0","url":null,"abstract":"PURPOSEMotor improvement and neuropsychiatric symptoms may immediately follow implantation of subthalamic nucleus deep brain stimulation (STN-DBS) electrodes in Parkinson's disease (PD). We investigated the impact of electrode implantation prior to stimulation on transient dysfunction using cerebral [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG-PET). Additionally, we sought to identify clinical and imaging variables associated with neuropsychiatric side effects (SE).METHODSThis retrospective analysis included thirteen patients with advanced PD, receiving [18F]FDG-PET scans preoperatively and within three weeks (median 6 days) after STN-DBS surgery. We analyzed changes of regional metabolism in a voxel-wise manner and with volumes-of-interests. Moreover, we evaluated the extent and magnitude of metabolic decrease alongside the electrode trajectories. Neuropsychiatric SE were defined as novel, surgery-related neuropsychiatric symptoms listed in clinical records.RESULTSPET analyses revealed hypometabolism along the electrodes (mean magnitude up to -35.9 ± 18.0% and mean extent of 19.9 ± 10.2 ml per hemisphere) largely located in the frontal lobe (left: kE = 1718 voxels; right: kE = 1550 voxels, p < 0.05, false discovery rate corrected). Patients with neuropsychiatric SE were older (61 vs. 55 years; p = 0.043) and had lower normalized [18F]FDG uptake in the middle frontal gyrus (MFG) preoperatively (1.01 vs. 1.06; p = 0.030). Preoperative metabolism in the MFG and age were indicative of the occurrence of neuropsychiatric SE (area under the Receiver Operating Characteristic curve = 0.90).CONCLUSIONSReversible neuronal dysfunction after STN-DBS surgery can be detected by [18F]FDG-PET along the electrode trajectory. Preoperative MFG metabolism and age were associated with postoperative neuropsychiatric SE supporting the use of PET to improve patient selection and postoperative care concepts.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"86 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual interpretation of [18F]Florzolotau Tau-PET imaging for differentiating alzheimer's disease and progressive supranuclear palsy.","authors":"Huan-Chun Lin,Kuo-Lun Huang,Shih-Hsin Chen,Tsung-Ying Ho,Chin-Chang Huang,Jung-Lung Hsu,Chiung-Chih Chang,Kun-Ju Lin,Ing-Tsung Hsiao","doi":"10.1007/s00259-025-07539-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07539-x","url":null,"abstract":"INTRODUCTIONTau accumulation in the brain is a hallmark of both Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), complicating differential diagnosis. The novel [18F]Florzolotau tauPET enables invivo detection. This study tests a visual reading approach on [18F]Florzolotau PET for reliably separating AD from PSP and assessing its clinical usefulness.METHODSEightynine participants of Aβpositive AD, Aβnegative PSP, and cognitively unimpaired controls (CU) underwent [18F]Florzolotau PET, [18F]Florbetapir amyloidPET, and MRI. Visual interpretation of the tau-PET scans was performed using a colormap-based method, dividing the brain into AD-specific regions and PSP-specific regions. Regional tau uptake was scored visually, and the results were compared with SUVr values from quantitative analysis. Decision tree analysis was used to classify patients based on visual scores.RESULTSThe study found significant differences in visual scores between the CU, AD, and PSP groups, particularly in the AD-specific and PSP-specific regions. Visual assessment of tau uptake moderately correlated with SUVr values, especially in AD-specific regions. The decision tree model using visual scores accurately classified CU, AD, and PSP patients, with sensitivity and specificity rates exceeding 85%. Interobserver agreement for visual scoring was high, supporting the reliability of this method in clinical settings.CONCLUSIONVisual interpretation scoring system of [18F] Florzolotau tau-PET reliably distinguishes AD from PSP, shows strong correlations with diagnoses, and is simpler than quantitative analyses for routine practice. Larger cohorts must confirm accuracy, refine the method, and assess its ability to grade disease severity.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"157 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145195000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidates.","authors":"Natalie Jones, Trent M Schwartz, Steven Bishay, W Hudson Robb, Amanda Sams, Josh Kogan, Monica Nable, Sydney Nelson, Oliver S Zhao, Timothy Hohman, Steven Huang, Felipe Martinez, Ba Nguyen, Clifford Shin, Ming Yang, Holly Westervelt, Sarah M Szymkowicz, Lesley T Omary, Bashar A Aqel, Rolland Dickson, Blanca Lizaola, Amit Mathur, Manhal Izzy, Mary Ellen I Koran","doi":"10.1007/s00259-025-07382-0","DOIUrl":"10.1007/s00259-025-07382-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4652-4660"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).","authors":"Petra Petranović Ovčariček, Murat Tuncel, Michael C Kreissl, Alfredo Campennì, Bart de Keizer, Désirée Deandreis, Luca Giovanella","doi":"10.1007/s00259-025-07367-z","DOIUrl":"10.1007/s00259-025-07367-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4364-4367"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}